Yan Guanqiang, Li Jingxiao, Gao Xiang, Liu Jun, Feng Guiyu, Li Yue, Zhou Huafu
Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Guangxi Medical University, Nanning, China.
Front Med (Lausanne). 2024 Nov 19;11:1433601. doi: 10.3389/fmed.2024.1433601. eCollection 2024.
The aim of this investigation was to assess the diagnostic and therapeutic efficacy of G2 and S-phase expressed 1 (GTSE1) in lung adenocarcinoma (LUAD), while examining its impact on immune infiltration and drug treatment mechanisms.
This research involved examining the expression patterns and diagnostic accuracy of GTSE1 in LUAD using various databases and clinical samples. The databases utilized included Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and The Cancer Genome Atlas (TCGA). Both gene expression and protein levels were analyzed. Subsequently, the prognostic ability of GTSE1 was evaluated based on clinical follow-up data using methods such as using univariate, multivariate, and prognostic meta-analysis. Additionally, potential mechanisms of action of GTSE1 were explored through enrichment analysis. Furthermore, the correlation between GTSE1 expression and the tumor microenvironment, immune cell infiltration, and immune checkpoints was assessed using ESTIMATE and CIBERSORT algorithms. The effectiveness of chemotherapy and targeted therapy was predicted using the "pRophetic" R package, which analyzed gene expression data.
Analysis of GEO data, CPTAC data, TCGA data, and clinical samples revealed increased levels of GTSE1 in LUAD tissues. Enhanced GTSE1 expression demonstrated excellent diagnostic accuracy and served as a significant prognostic indicator for LUAD patients. GTSE1 expression emerged as an independent predictive factor in both univariate and multivariate Cox regression analyses. Furthermore, functional enrichment analysis suggested a potential association between GTSE1 and the cell cycle, p53 signaling pathway, as well as ubiquitin-mediated protein degradation. High expression of GTSE1 was associated with increased immune cell infiltration and heightened sensitivity to a specific type of chemotherapy and targeted drugs.
Increased expression of GTSE1 in patients with LUAD showed significant diagnostic and prognostic significance. It was also associated with increased immune infiltration and an unfavorable response to targeted medication.
本研究旨在评估G2和S期表达蛋白1（GTSE1）在肺腺癌（LUAD）中的诊断和治疗效果，同时研究其对免疫浸润和药物治疗机制的影响。
本研究通过多种数据库和临床样本，检测GTSE1在LUAD中的表达模式和诊断准确性。所使用的数据库包括基因表达综合数据库（GEO）、临床蛋白质组肿瘤分析联盟（CPTAC）和癌症基因组图谱（TCGA）。对基因表达和蛋白质水平进行了分析。随后，基于临床随访数据，采用单因素、多因素和预后荟萃分析等方法评估GTSE1的预后能力。此外，通过富集分析探索GTSE1的潜在作用机制。进一步地，使用ESTIMATE和CIBERSORT算法评估GTSE1表达与肿瘤微环境、免疫细胞浸润和免疫检查点之间的相关性。使用“pRophetic”R包分析基因表达数据，预测化疗和靶向治疗的有效性。
对GEO数据、CPTAC数据、TCGA数据和临床样本的分析显示，LUAD组织中GTSE1水平升高。GTSE1表达增强显示出优异的诊断准确性，并可作为LUAD患者的重要预后指标。在单因素和多因素Cox回归分析中，GTSE1表达均为独立预测因子。此外，功能富集分析表明GTSE1与细胞周期、p53信号通路以及泛素介导的蛋白质降解之间可能存在关联。GTSE1高表达与免疫细胞浸润增加以及对特定类型化疗和靶向药物的敏感性增强有关。
LUAD患者中GTSE1表达增加具有显著的诊断和预后意义。它还与免疫浸润增加和对靶向药物的不良反应有关。
